Treatment of malignant hypercalcaemia. - Wikidata - wikimedia - TriplyDB

Treatment of malignant hypercalcaemia.

Treatment of malignant hypercalcaemia.

http://www.wikidata.org/entity/Q34628598

about

Premithramycinone G, an early shunt product of the mithramycin biosynthetic pathway accumulated upon inactivation of oxygenase MtmOII Parathyroid adenoma disclosed by a massive cervical hematoma.

P2860

Q42113467-2D6BA96F-95AD-4F96-8F4C-DAA24A55CF0B Q53545456-67282DF3-75F5-4A71-9779-1D88DB559CE4

P2860

Treatment of malignant hypercalcaemia.

http://www.wikidata.org/entity/Q34628598

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Treatment of malignant hypercalcaemia.

@ast

Treatment of malignant hypercalcaemia.

@en

Treatment of malignant hypercalcaemia.

@nl

type

label

Treatment of malignant hypercalcaemia.

@ast

Treatment of malignant hypercalcaemia.

@en

Treatment of malignant hypercalcaemia.

@nl

prefLabel

Treatment of malignant hypercalcaemia.

@ast

Treatment of malignant hypercalcaemia.

@en

Treatment of malignant hypercalcaemia.

@nl

P1433

Q34628598-863F2223-F057-4910-86DC-657588FA088B

P1476

Q34628598-62BAF38F-BF34-44B2-9168-CC84B1FB3358

P2093

Q34628598-E1EE11AF-CA58-48E6-B016-CEEB82548638

Q34628598-E464227A-BE23-4AFC-A24B-9F43876BAEC4

P2860

Q34628598-040BC533-1F04-424E-8543-72CDDB0EE7DA

Q34628598-0ACB1DFD-E7D0-4850-B9C6-F541EA0AC4D8

Q34628598-10E38D4B-FCAB-4293-9256-0E0FA39F4221

Q34628598-1CB562F7-6531-47E9-8F7C-6FB6ACCDA029

Q34628598-2C93E564-B8C8-4872-A560-0EDC6E70AFA3

Q34628598-47C85844-27F1-47FD-BCE6-DFAD03E832AC

Q34628598-5D93A559-FAB3-4B48-8E7C-84CDECA2905F

Q34628598-6C9C342A-C3FB-4058-8F06-3E0BC3AC6F1A

Q34628598-747365AD-46B5-45AE-BEF0-08DF19EA08FA

Q34628598-8C319D83-A891-42D9-A602-AE1DC01C77DA

P304

Q34628598-F7BCD327-0F4D-4058-946C-83A9D70C8ED1

P31

Q34628598-A47877A7-1999-44F7-BCB9-55D6B6C5F5C9

P356

Q34628598-451F2FD1-D448-493E-82E9-3C9C4ED8F6F5

P407

Q34628598-8C7AD9F6-79D8-47B6-BA1E-BAEBCB50B1F2

P433

Q34628598-004C2B5D-EBCE-4F62-9EE7-12798F96C588

P478

Q34628598-166C58FA-4E8C-4DBD-9425-7EA6C7A3CDB7

P577

Q34628598-728C8DEA-8890-4EA2-B7A5-1D14334067C1

P698

Q34628598-8BB18773-0490-4480-A2D3-2BE39D3CB5CE

P356

14656566.3.5.521

P1433

Expert Opinion on Pharmacotherapy

P1476

Treatment of malignant hypercalcaemia.

@en

P2093

Esbrit P

http://www.w3.org/2001/XMLSchema#string

Hurtado J

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

Bisphosphonates: from the laboratory to the clinic and back again.

Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

The physiology of parathyroid hormone-related protein.

Molecular mechanisms of osteolytic bone metastases.

Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia.

Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.

Osteolysis and cancer.

The hypercalcemia of malignancy: pathogenesis and management.

P304

521-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.3.5.521

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11996631

http://www.w3.org/2001/XMLSchema#string